CA2523859A1 - Methods and devices for the sustained release of multiple drugs - Google Patents
Methods and devices for the sustained release of multiple drugs Download PDFInfo
- Publication number
- CA2523859A1 CA2523859A1 CA002523859A CA2523859A CA2523859A1 CA 2523859 A1 CA2523859 A1 CA 2523859A1 CA 002523859 A CA002523859 A CA 002523859A CA 2523859 A CA2523859 A CA 2523859A CA 2523859 A1 CA2523859 A1 CA 2523859A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- delivery device
- drug delivery
- segment
- permeable polymeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Abstract
The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance , wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.
Claims (86)
1. A drug delivery device comprising two or more segments, wherein each unitary segment comprises a drug-permeable polymeric substance, and wherein at least one unitary segment comprises a mixture of the drug-permeable polymeric substance and a drug.
2. The drug delivery device of claim 1, wherein two or more unitary segments each contain a drug.
3. The drug delivery device of claim 1, wherein the drug-permeable polymeric substance is a thermoplastic polymer.
4. The drug delivery device of claim 3, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
5. The method of claim 1, wherein the drug delivery device is in the shape of a ring, a wafer, or a suppository.
6. The drug delivery device of claim 1, wherein at least one end of the unitary segments is attached to the end of another unitary segment, and wherein the drug delivery device is in the shape of a ring.
7. The drug delivery device of claim 6, wherein the device is suitable for use as a vaginal ring.
8. The drug delivery device of claim 6, wherein the ends of the segments are attached by a coupling means.
9. The drug delivery device of claim 8, wherein the coupling means is an adhesive material.
10. The drug delivery device of claim 7, having an overall diameter of from 40 mm to 80 mm.
11. The drug delivery device of claim 7, having a cross-sectional diameter of from 0.5 mm to
12 mm.
12. The drug delivery device of claim 1, wherein the drug is a hormone replacement steroid.
12. The drug delivery device of claim 1, wherein the drug is a hormone replacement steroid.
13. The drug delivery device of claim 1, wherein the drug is a contraceptive agent.
14. The drug delivery device of claim 1, wherein the drug is selected from the group consisting of: interferon, anti-angiogenesis factors, growth factors, hormones, enzymes, transferases, hydrolases, lysases, isomerases, proteases, ligases and oxidoreductases, enzyme inhibitors, steroids, anti-cancer drugs and antibiotics.
15. The drug delivery device of claim 1, wherein the drug is selected from the group consisting of: growth hormone, polysaccharides, antigens, and antibodies.
16. A drug delivery system for the controlled release of two or more drugs, which system comprises two or more unitary segments, wherein each unitary segment comprises a mixture of a drug-permeable polymeric substance and a drug.
17. The drug delivery system of claim 16, wherein at least two of the segments comprise a different drug.
18. The drug delivery system of claim 16, wherein the drug-permeable polymeric substance is a thermoplastic polymer.
19. The drug delivery system of claim 18, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
20. The drug delivery system of claim 16, wherein the drug is a hormone replacement steroid.
21. The drug delivery system of claim 16, wherein the drug is a contraceptive agent.
22. The drug delivery device of claim 16, wherein the drug is selected from the group consisting of selected from the group consisting of: interferon, anti-angiogenesis factors, growth factors, hormones, enzymes, transferases, hydrolases, lysases, isomerases, proteases, ligases and oxidoreductases, enzyme inhibitors, steroids, anti-cancer drugs and antibiotics.
23. The drug delivery device of claim 16, wherein the drug is selected from the group consisting of: growth hormone, polysaccharides, antigens, and antibodies.
24. A method for delivering a drug to a female mammal, said method comprising the steps of:
(a) preparing a drug delivery device comprising two or more unitary segments, wherein each unitary segment comprises a drug-permeable polymeric substance, and wherein at least one unitary segment comprises a mixture of the drug-permeable polymeric substance and a drug;
(b) positioning in the vaginal tract of the female mammal the drug delivery device of step (a); and (c) maintaining the drug delivery device in the vaginal tract of the female mammal for a period of time sufficient to deliver an effective amount of the drug to the female mammal.
(a) preparing a drug delivery device comprising two or more unitary segments, wherein each unitary segment comprises a drug-permeable polymeric substance, and wherein at least one unitary segment comprises a mixture of the drug-permeable polymeric substance and a drug;
(b) positioning in the vaginal tract of the female mammal the drug delivery device of step (a); and (c) maintaining the drug delivery device in the vaginal tract of the female mammal for a period of time sufficient to deliver an effective amount of the drug to the female mammal.
25. The method of claim 24, wherein the drug-permeable polymeric substance is a thermoplastic polymer.
26. The method of claim 25, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
27. The method of claim 24, wherein the drug is a hormone replacement steroid.
28. The method of claim 24, wherein the drug is a contraceptive agent.
29. The drug delivery device of claim 24, wherein the drug is selected from the group consisting of: interferon, anti-angiogenesis factors, growth factors, hormones, enzymes, transferases, hydrolases, lysases, isomerases, proteases, ligases and oxidoreductases, enzyme inhibitors, steroids, anti-cancer drugs and antibiotics.
30. The drug delivery device of claim 24, wherein the drug is selected from the group consisting of: growth hormone, polysaccharides, antigens, and antibodies.
31. A method of making a ring-shaped drug delivery device, comprising the steps of:
(a) mixing a first drug-permeable polymeric substance with a first drug to form a first polymeric mixture;
(b) molding the first polymeric mixture of step (a) to form a first ring;
(c) cutting the first ring of step (b) to form a first unitary segment;
(d) repeating steps (a) to (c) with a second drug-permeable polymeric substance and a second drug to form a second unitary segment; and (e) connecting an end of a first unitary segment with an end of a second unitary segment to form a ring-shaped drug delivery device.
(a) mixing a first drug-permeable polymeric substance with a first drug to form a first polymeric mixture;
(b) molding the first polymeric mixture of step (a) to form a first ring;
(c) cutting the first ring of step (b) to form a first unitary segment;
(d) repeating steps (a) to (c) with a second drug-permeable polymeric substance and a second drug to form a second unitary segment; and (e) connecting an end of a first unitary segment with an end of a second unitary segment to form a ring-shaped drug delivery device.
32. The method of claim 31, further comprising repeating step (d) with a third drug-permeable polymeric substance and a third drug to form a third unitary segment, and connecting said first unitary segment, second unitary segment, and third unitary segment to form a ring-shaped drug delivery device.
33. The method of claim 32, further comprising repeating step (d) with at least one additional drug-permeable polymeric substance and one additional drug to form two or more additional unitary segments, and connecting said first unitary segment, second unitary segment, third unitary segment, and an additional unitary segment to form a ring-shaped drug delivery device.
34. The method of claim 31, wherein the first and second drug-permeable polymeric substances are a thermoplastic polymer.
35. The method of claim 34, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
36. The method of claim 31, wherein the first and second drug-permeable polymeric substances are the same.
37. The method of claim 31, wherein the connecting step is performed using an adhesive material.
38. A method of making a ring-shaped drug delivery device, comprising the steps of:
(a) mixing a first drug-permeable polymeric substance with a first drug to form a first polymeric mixture;
(b) molding the first polymeric mixture of step (a) to form a first unitary segment;
(c) repeating steps (a) and (b) with a second drug-permeable polymeric substance and a second drug to form a second unitary segment; and (d) connecting an end of a first unitary segment with an end of a second unitary segment to form a ring-shaped drug delivery device.
(a) mixing a first drug-permeable polymeric substance with a first drug to form a first polymeric mixture;
(b) molding the first polymeric mixture of step (a) to form a first unitary segment;
(c) repeating steps (a) and (b) with a second drug-permeable polymeric substance and a second drug to form a second unitary segment; and (d) connecting an end of a first unitary segment with an end of a second unitary segment to form a ring-shaped drug delivery device.
39. The method of claim 38, further comprising repeating step (c) with a third drug-permeable polymeric substance and a third drug to form a third unitary segment, and connecting said first unitary segment, second unitary segment, and third unitary segment to form a ring-shaped drug delivery device.
40. The method of claim 39, further comprising repeating step (c) with at least one additional drug-permeable polymeric substance and one additional drug to form at least one additional unitary segment, and connecting said first unitary segmenet , second unitary segment, third unitary segment, and at least one additional unitary segment to form a ring-shaped drug delivery device.
41. The method of claim 38, wherein the first and second drug-permeable polymeric substances are a thermoplastic polymer.
42. The method of claim 41, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
43. The method of claim 38, wherein the first and second drug-permeable polymeric substances are the same.
44. The method of claim 38, wherein the connecting step is performed using an adhesive material.
45. A method of making a drug delivery device, comprising the steps of:
(a) mixing a first drug-permeable polymeric substance with a first drug to form a first polymeric mixture;
(b) injecting the first polymeric mixture of step (a) into a mold to form a first unitary segment; and (c) repeating steps (a) and (b) with a second drug-permeable polymeric substance and a second drug to form a second unitary segment to form the drug delivery device.
(a) mixing a first drug-permeable polymeric substance with a first drug to form a first polymeric mixture;
(b) injecting the first polymeric mixture of step (a) into a mold to form a first unitary segment; and (c) repeating steps (a) and (b) with a second drug-permeable polymeric substance and a second drug to form a second unitary segment to form the drug delivery device.
46. The method of claim 45, further comprising repeating step (c) with a third drug-permeable polymeric substance and a third drug to form a third unitary segment and to form a drug delivery device.
47. The method of claim 46, further comprising repeating step (c) with at least one additional drug-permeable polymeric substance and one additional drug to form at least one additional unitary segment to form a drug delivery device.
48. The method of claim 45, wherein the first and second drug-permeable polymeric substances are a thermoplastic polymer.
49. The method of claim 48, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
50. The method of claim 45, wherein the first and second drug-permeable polymeric substances are the same.
51. A method for the treatment of a benign ovarian secretory disorder in a female mammal, comprising:
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and a luteinizing hormone releasing hormone (LHRH), and wherein said second segment comprises the drug-permeable polymeric substance and an estrogenic steroid; and (b) inserting into the vagina of said mammal the drug delivery device of step (a) to release a therapeutically effective amount of the LHRH and an effective amount of the estrogenic steroid to said female mammal.
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and a luteinizing hormone releasing hormone (LHRH), and wherein said second segment comprises the drug-permeable polymeric substance and an estrogenic steroid; and (b) inserting into the vagina of said mammal the drug delivery device of step (a) to release a therapeutically effective amount of the LHRH and an effective amount of the estrogenic steroid to said female mammal.
52. The method of claim 51, wherein the drug delivery device further comprises a third segment, wherein said third segment comprises the drug-permeable polymeric substance and a progestational steroid, and wherein the drug delivery device releases an effective amount of the progestational steroid.
53. The method of claim 51, wherein the drug-permeable polymeric substance is a thermoplastic polymer.
54. The method of claim 53, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
55. The method of claim 51, wherein the drug delivery device is in the shape of a ring, a wafer, or a suppository.
56. The method of claim 51, wherein the drug delivery device is in the shape of a ring.
57. The method of claim 51, wherein said benign ovarian secretory disorder is polycystic ovarian disease.
58. The method of claim 51, wherein said benign ovarian secretory disorder is characterized by excessive ovarian progesterone secretion.
59. The method of claim 51, wherein said benign ovarian secretory disorder is characterized by excessive ovarian estrogen secretion or excessive androgen secretion.
60. The method of claim 51, wherein said benign ovarian secretory disorder is characterized by hyperthecosis, hirsutism, dysfunctional uterine bleeding, amenorrhea, or anestrus.
61. The method of claim 51, wherein said estrogen steroid is selected from the group consisting of estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, conjugated equine estrogen, estriol, estrone, estrone sulfate, ethinyl estradiol, estrofurate, quinestrol and mestranol.
62. The method of claim 51, wherein said estrogenic steroid is selected from the group of selective estrogen receptor modulators consisting of tamoxifen, raloxifene, clomiphene, droloxifene, idoxifene, toremifene, tibolone, ICI 182,780, ICI 164,384, diethylstilbesterol, genistein, nafoxidine, moxestrol, 19-nor-progesterone derivatives, and 19-nor-testosterone derivatives.
63. The method of claim 52, wherein said progestation steroid is selected from the group consisting of progesterone, 17-hydroxy progesterone derivatives, 19-nor-testosterone derivatives, 19-nor-progesterone derivatives norethindrone, norethindrone acetate, norethynodrel, norgestrel, norgestimate, ethynodiol diacetate, allylestrenol, lynoestrenol, fuingestanol acetate, medrogestone, norgestrienone, dimethiderome, ethisterone, cyproterone levo-norgestrel, dl-norgestrel, cyproterone acetate, gestodene, desogestrol, dydrogesterone, ethynodiol diacetate, medroxyprogesterone acetate, megestrol acetate, phytoprogestins, and animal-derived progestins and metabolic derivatives thereof.
64. The method of claim 52, wherein said progestational steroid is selected from the group of selective progestin receptor modulators consisting of RU486, CDB2914, 19-nor-progesterone derivatives, 19-nor-testosterone derivatives, 6-aryl-1,2-dihydro-2,2,4-trimethylquinoline derivatives, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinoline derivatives, 5-alkyl 1,2-dihydrochomeno[3,4-f]quinoline derivatives, and 6-thiophenehydroquinoline derivatives.
65. The method of claim 51, wherein the female mammal is a human female.
66. A method for increasing the breeding rate of a female mammal, wherein said female mammal is induced to breed by the method of claim 51.
67. A method for preventing pregnancy in a female mammal, comprising:
(a) providing a drug delivery device comprising a first segment comprising a drug-permeable polymeric substance and a luteinizing hormone releasing hormone (LHRH), a second segment comprising the drug-permeable polymeric substance and an estrogenic steroid, and a third segment comprising the drug-permeable polymeric substance and a progestational steroid; and (b) inserting into the vagina of said mammal the drug delivery device of step (a) to release an effective amount of the LHRH, an effective amount of the estrogenic steroid, and an effective amount of the progestational steroid to said female mammal.
(a) providing a drug delivery device comprising a first segment comprising a drug-permeable polymeric substance and a luteinizing hormone releasing hormone (LHRH), a second segment comprising the drug-permeable polymeric substance and an estrogenic steroid, and a third segment comprising the drug-permeable polymeric substance and a progestational steroid; and (b) inserting into the vagina of said mammal the drug delivery device of step (a) to release an effective amount of the LHRH, an effective amount of the estrogenic steroid, and an effective amount of the progestational steroid to said female mammal.
68. The method of claim 67, wherein the drug-permeable polymeric substance is a thermoplastic polymer.
69. The method of claim 68, wherein the thermoplastic polymer is an ethylene-vinyl acetate copolymer.
70. The method of claim 67, wherein the drug delivery device is in the shape of a ring, a waffer, or a suppository.
71. The method of claim 67, wherein the drug delivery device is in the shape of a ring.
72. A method of treating a decrease in estrogen secretion in a woman exhibiting symptoms of a cessation of cyclical ovulation, which method comprises:
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and a hormone replacement steroid, and wherein said second segment comprises a drug-permeable polymeric substance and progestational steroid; and (b) inserting into the vagina of said woman the drug delivery device of step (a) to release an effective amount of the hormone replacement steroid to said woman.
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and a hormone replacement steroid, and wherein said second segment comprises a drug-permeable polymeric substance and progestational steroid; and (b) inserting into the vagina of said woman the drug delivery device of step (a) to release an effective amount of the hormone replacement steroid to said woman.
73. The method of claim 72, wherein the hormone replacement steroid is an estrogenic steroid.
74. The method of claim 73, wherein the estrogenic steroid is selected from the group consisting of estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, conjugated equine estrogen, estriol, estrone, estrone sulfate, ethinyl estradiol, estrofurate, quinestrol and mestranol.
75. The method of claim 73, wherein the estrogenic steroid is selected from the group of selective estrogenic receptor modulators consisting of tamoxifen, raloxifene, clomiphene, droloxifene, idoxifene, toremifene, tibolone, ICI 182,780, ICI 164,384, diethylstilbesterol, genistein, nafoxidine, moxestrol, 19-nor-progesterone derivatives, and 19-nor-testosterone derivatives.
76. The method of claim 72, further comprising a third segment, wherein said third segment comprises a drug-permeable polymeric substance and an androgen or a selective androgen receptor modulator (SARM).
77. A method for relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman having said periods and in need of estrogen therapy, which method comprises:
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and an estrogenic steroid; and (b) inserting into the vagina of said woman the drug delivery device of step (a) to release an effective amount of the estrogenic steroid to said woman.
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and an estrogenic steroid; and (b) inserting into the vagina of said woman the drug delivery device of step (a) to release an effective amount of the estrogenic steroid to said woman.
78. The method of claim 77, wherein the estrogenic steroid is selected from the group consisting of a naturally occurring estrogen, a synthetic estrogen, and a selective estrogen receptor modulator.
79. The method of claim 77, wherein the drug-permeable polymeric substance is a thermoplastic polymer.
80. The method of claim 78, wherein the thermoplastic polymer is an ethylene
81. The method of claim 77, wherein the drug delivery device is in the shape of a ring, a waffer, or a suppository.
82. The method of claim 77, wherein the drug delivery device is in the shape of a ring. A
method for relieving the symptoms associated with the menopausal, perimenopausal and postmenopausal periods in a woman having said periods and in need of estrogen therapy, which method comprises:
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and a hormone replacement steroid; and (b) inserting into the vagina of said woman the drug delivery device of step (a) to release an effective amount of the hormone replacement steroid to said woman.
method for relieving the symptoms associated with the menopausal, perimenopausal and postmenopausal periods in a woman having said periods and in need of estrogen therapy, which method comprises:
(a) providing a drug delivery device comprising a first segment and a second segment, wherein said first segment comprises a drug-permeable polymeric substance and a hormone replacement steroid; and (b) inserting into the vagina of said woman the drug delivery device of step (a) to release an effective amount of the hormone replacement steroid to said woman.
83. The method of claim 82, wherein the hormone replacement steroid is an estrogenic steroid.
84. The method of claim 83, wherein the estrogenic steroid is selected from the group consisting of a naturally occurring estrogen, a synthetic estrogen, and a selective estrogen receptor modulator.
85. The method of claim 83, wherein the estrogenic steroid is a member selected from the group consisting of estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, conjugated equine estrogen, estriol, estrone, estrone sulfate, ethinyl estradiol, estrofurate, quinestrol and mestranol.
86, The method of claim 83, wherein the estrogenic steroid is selected from the group of selective estrogenic receptor modulators consisting of tamoxifen, raloxifene, clomiphene, droloxifene, idoxifene, toremifene, tibolone, ICI 182,780, ICI 164,384, diethylstilbesterol, genistein, nafoxidine, moxestrol, 19-nor-progesterone derivatives, and 19-nor-testosterone derivatives.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46631803P | 2003-04-29 | 2003-04-29 | |
US60/466,318 | 2003-04-29 | ||
US47357903P | 2003-05-27 | 2003-05-27 | |
US60/473,579 | 2003-05-27 | ||
PCT/US2004/013172 WO2004096151A2 (en) | 2003-04-29 | 2004-04-29 | Methods and devices for the sustained release of multiple drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2523859A1 true CA2523859A1 (en) | 2004-11-11 |
CA2523859C CA2523859C (en) | 2011-08-02 |
Family
ID=33423604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2523859A Expired - Lifetime CA2523859C (en) | 2003-04-29 | 2004-04-29 | Methods and devices for the sustained release of multiple drugs |
Country Status (8)
Country | Link |
---|---|
US (7) | US7833545B2 (en) |
EP (1) | EP1620060B1 (en) |
JP (1) | JP4898431B2 (en) |
AT (1) | ATE461681T1 (en) |
AU (1) | AU2004233997C1 (en) |
CA (1) | CA2523859C (en) |
DE (1) | DE602004026173D1 (en) |
WO (1) | WO2004096151A2 (en) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
US7169178B1 (en) | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
BRPI0414500A (en) | 2003-09-19 | 2006-11-07 | Drugtech Corp | pharmaceutical formulation composition to treat a vaginal infection, and methods to treat a vaginal infection, to stabilize a clindamycin formulation, to treat or prevent a recurrence of a vaginal infection in a patient and to treat vaginal conditions |
DE602005026290D1 (en) | 2004-07-09 | 2011-03-24 | Population Council Inc | COMPOSITIONS OF DELAYED RELEASE WITH PROGESTERONE RECEPTOR MODULATORS |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
US8057817B2 (en) * | 2004-12-14 | 2011-11-15 | Poly-Med, Inc. | Intravaginal ringed mesh device and applicator therefor |
JP5193196B2 (en) | 2006-06-02 | 2013-05-08 | ペア ツリー ウーマンズ ヘルス ケア | Methods of treatment for atrophic vaginitis |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
BRPI0713203A2 (en) * | 2006-07-12 | 2012-04-03 | Controlled Therapeutics Scotland Ltda | insert, methods, packing, recoverable device and insertable device |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
CA2672602C (en) | 2006-12-18 | 2014-05-20 | Electronic Dietary Foods Inc. | Device for delivery of a substance |
US20090118253A1 (en) * | 2007-11-05 | 2009-05-07 | Repros Therapeutics Inc. | Compositions and methods for treating dysfunctional uterine bleeding |
EP2057972A1 (en) * | 2007-11-07 | 2009-05-13 | N.V. Organon | Intrauterine deposit |
EP2062568A1 (en) * | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Oy | Vaginal delivery system |
DK2062569T3 (en) * | 2007-11-22 | 2011-08-29 | Bayer Oy | Vaginal delivery system |
SG10201605171QA (en) * | 2008-02-04 | 2016-08-30 | Ferring Bv | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
WO2009129459A1 (en) * | 2008-04-18 | 2009-10-22 | Combinent Biomedical Systems, Inc. | Devices that include ethylene-vinyl acetate copolymers and methods of making and using same |
TWI477276B (en) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | Antiprogestin dosing regimens |
US9034365B2 (en) | 2008-05-20 | 2015-05-19 | Poly-Med, Inc. | Biostable, multipurpose, microbicidal intravaginal devices |
EP2140860A1 (en) | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | An improved method of contraception |
US20100040671A1 (en) * | 2008-08-12 | 2010-02-18 | Ahmed Salah U | Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof |
CA2739147A1 (en) * | 2008-11-07 | 2010-05-14 | Combinent Biomedical Systems, Inc. | Therapeutic peptide drug delivery and device |
FI121000B (en) * | 2008-11-19 | 2010-06-15 | Bayer Schering Pharma Oy | Intravaginal delivery system and method for its preparation |
US8568374B2 (en) * | 2009-05-04 | 2013-10-29 | Merck Sharp & Dohme B.V. | Intrauterine system |
CN102596097B (en) | 2009-06-03 | 2015-05-20 | 弗赛特实验室有限责任公司 | Anterior segment drug delivery |
US8753667B2 (en) | 2009-07-21 | 2014-06-17 | The Population Council, Inc. | Multi-layered gradient vaginal ring |
CN102811730B (en) * | 2010-02-08 | 2014-07-09 | 杜涛 | Methods for the use of progestogen as a glucocorticoid sensitizer |
RU2648827C2 (en) * | 2010-03-28 | 2018-03-28 | Эвестра, Инк. | Intravaginal drug delivery device |
CA2798084A1 (en) | 2010-05-17 | 2011-11-24 | Aerie Pharmaceuticals, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
TW201212939A (en) * | 2010-06-22 | 2012-04-01 | Anu Mahashabde | Intravaginal devices comprising anticholinergic agents, and methods of making thereof |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
CA2817713C (en) * | 2010-11-12 | 2018-12-04 | The University Of Utah Research Foundation | Intravaginal devices for controlled delivery of lubricants |
KR101263916B1 (en) | 2011-01-11 | 2013-05-13 | 이장희 | Device for releasing sex hormone and method for animal estrus induction and contraception using the same |
WO2012121811A1 (en) * | 2011-03-04 | 2012-09-13 | Arstat, Inc. | Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent |
WO2013010915A1 (en) | 2011-07-15 | 2013-01-24 | Universiteit Gent | Intravaginal delivery system |
KR102071083B1 (en) | 2011-09-14 | 2020-01-29 | 포사이트 비젼5, 인크. | Ocular insert apparatus and methods |
US20130245549A1 (en) * | 2011-09-14 | 2013-09-19 | Royer Biomedical, Inc. | Bioresorable drug delivery matrices based on cross-linked polysaccharides, dosage forms designed for delayed/controlled release |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130166931A1 (en) * | 2011-12-23 | 2013-06-27 | Lsi Corporation | Reducing power consumption of memory |
US9854831B2 (en) | 2012-01-20 | 2018-01-02 | Altria Client Services Llc | Oral product |
CN102754907B (en) | 2012-01-20 | 2015-06-24 | 奥驰亚客户服务公司 | Oral product |
CN102754908B (en) | 2012-01-20 | 2015-06-10 | 奥驰亚客户服务公司 | Oral tobacco product |
CN103039688B (en) | 2012-01-20 | 2016-01-06 | 奥驰亚客户服务公司 | Oral product |
CN103040090B (en) * | 2012-01-20 | 2016-03-30 | 奥驰亚客户服务公司 | Remove the oral product of tobacco |
DE102012009057A1 (en) * | 2012-05-09 | 2013-11-14 | Dr. Arabin GmbH & Co. KG | Rotational pessary made from a polymer comprises an active substance against premature births |
WO2013181449A1 (en) | 2012-05-31 | 2013-12-05 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
CN104884006B (en) | 2012-10-26 | 2017-12-15 | 弗赛特影像5股份有限公司 | Ophthalmic system for sustained release drugs to eyes |
WO2014070517A1 (en) | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
KR20170005819A (en) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Natural combination hormone replacement formulations and therapies |
DK2982352T3 (en) | 2014-06-28 | 2018-11-26 | Laboratorios Andromaco S A | CERVICALLY PESSAR CONTAINING PROGESTERON FOR EXTENDED, LONG AND CONTINUOUS RELEASE USED TO PREVENT EARLY BIRTHS |
CN105277633B (en) * | 2014-07-26 | 2017-06-23 | 浙江仙琚制药股份有限公司 | A kind of defects inspecting analysis method of norethindrone derivative and its intermediate |
JP2017523138A (en) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Transdermal cream |
TW201618783A (en) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on BTK occupancy and BTK resynthesis rate |
EP3017809A1 (en) | 2014-11-07 | 2016-05-11 | Ferring B.V. | Drug-device unit containing quinagolide |
US20180008536A1 (en) | 2015-01-21 | 2018-01-11 | Bayer Oy | Drug delivery system comprising a non-steroidal anti-inflammatory (nsaid) and a progestogenic compound and methods for manufacturing |
EP3250183A1 (en) * | 2015-01-30 | 2017-12-06 | Li Galli B.V. | Vaginal drug delivery device |
US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
CA2985717A1 (en) * | 2015-05-13 | 2016-11-17 | Bayer Oy | A long acting drug delivery device and its use in contraception |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
GB201517523D0 (en) * | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
US20190008804A1 (en) * | 2016-01-12 | 2019-01-10 | Repros Therapeutics Inc. | Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
GB201708224D0 (en) | 2017-05-23 | 2017-07-05 | Juniper Pharmaceuticals Uk Ltd | Device |
FR3070619A1 (en) * | 2017-09-01 | 2019-03-08 | Ab7 Innovation | MULTI-MATRIX MONOLITHIC MOLDED PIECE FOR ACTIVE DIFFUSION AND METHOD OF OBTAINING SAME |
US20200337888A1 (en) | 2017-10-27 | 2020-10-29 | Renovia Inc. | Devices, systems, and methods for training pelvic floor muscles |
CN108186553B (en) * | 2018-02-13 | 2020-10-02 | 广东药科大学 | Long-acting progesterone suppository and preparation method thereof |
AU2019256585A1 (en) * | 2018-04-10 | 2020-10-08 | Ligalli B.V. | Vaginal systemic drug delivery |
WO2019210066A1 (en) * | 2018-04-27 | 2019-10-31 | Evestra, Inc. | Estrogen prodrugs and methods of administering estrogen prodrugs |
SG11202005949UA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
EP3801462A4 (en) | 2018-05-24 | 2022-03-16 | Celanese EVA Performance Polymers LLC | Implantable device for sustained release of a macromolecular drug compound |
WO2020205805A1 (en) * | 2019-03-29 | 2020-10-08 | Martell Bridget | Segmented eva intravaginal rings |
US11439588B2 (en) | 2019-10-12 | 2022-09-13 | National Research Institute For Family Planning | Vaginal sustained-release drug delivery system for luteal support, method for preparation and use thereof |
FR3107203B1 (en) * | 2020-02-14 | 2023-11-24 | Ab7 Innovation | SOLID COMPOSITE MATRIX FOR PROLONGED DELIVERY OF ACTIVES |
USD935018S1 (en) * | 2020-04-07 | 2021-11-02 | The Population Council, Inc. | Contraceptive |
WO2023031218A1 (en) | 2021-08-31 | 2023-03-09 | Ferring B.V. | Diagnosis and treatment of ectopic endometriosis |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1945275U (en) * | 1965-04-30 | 1966-09-01 | Ortho Pharma Corp | INTRAUTERINE DEVICE FOR CONCEPTION. |
US3454004A (en) * | 1967-08-18 | 1969-07-08 | Holland Rantos Co Inc | Intrauterine contraceptive device |
US3545439A (en) | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
NL6903028A (en) | 1969-02-26 | 1970-08-28 | ||
US4069307A (en) * | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
US3903880A (en) | 1972-08-17 | 1975-09-09 | Alza Corp | Intrauterine device for managing the reproductive process |
US3920805A (en) | 1971-12-09 | 1975-11-18 | Upjohn Co | Pharmaceutical devices and method |
US3938515A (en) | 1971-12-20 | 1976-02-17 | Alza Corporation | Novel drug permeable wall |
US3708511A (en) | 1972-01-18 | 1973-01-02 | Organon | Novel {66 -steroids of the oestrane series |
NL7204025A (en) | 1972-03-24 | 1973-09-26 | ||
US3780935A (en) | 1972-07-10 | 1973-12-25 | Lukacs & Jacoby Ass | Serum separating method |
NL7210262A (en) | 1972-07-26 | 1974-01-29 | ||
US4016251A (en) * | 1972-08-17 | 1977-04-05 | Alza Corporation | Vaginal drug dispensing device |
US3963119A (en) | 1973-10-13 | 1976-06-15 | Lucaks And Jacoby Associates | Serum separating apparatus |
US4043928A (en) | 1973-10-31 | 1977-08-23 | Lukacs And Jacoby Associates | Serum separating composition of matter |
IL48277A (en) | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
US4155991A (en) * | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4096860A (en) | 1975-10-08 | 1978-06-27 | Mclaughlin William F | Dual flow encatheter |
US3995633A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal Medicament dispensing device |
US3995634A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal cavity dispensing means and method |
US4219426A (en) | 1976-03-19 | 1980-08-26 | Organon Teknika B.V. | Dialysis device |
US4237885A (en) | 1978-10-23 | 1980-12-09 | Alza Corporation | Delivery system with mated members for storing and releasing a plurality of beneficial agents |
US4292965A (en) | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
DE3040978A1 (en) | 1980-10-28 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | VAGINAL RING |
US4484559A (en) * | 1982-03-01 | 1984-11-27 | Mcdermott Incorporated | Apparatus for removing material such as concrete from underwater pipelines |
DE3214667C2 (en) | 1982-04-21 | 1985-07-18 | Akzo Gmbh, 5600 Wuppertal | Composite body for the long-term delivery of active ingredients |
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
US4629449A (en) | 1982-07-29 | 1986-12-16 | Alza Corporation | Vaginal dispenser for dispensing beneficial hormone |
NL8301035A (en) | 1983-03-23 | 1984-10-16 | Organon Teknika Bv | MACROMOLECULAR MATERIAL WITH CARBONYL GROUPS SUITABLE AS SORBENT FOR NITROGEN COMPOUNDS. |
US4558996A (en) | 1983-06-30 | 1985-12-17 | Organon Teknika Corporation | Easy load peristaltic pump |
US4484599A (en) | 1983-09-23 | 1984-11-27 | Organon Teknika Corporation | Pinch-type pressure- or flow-regulating valve |
ZA857643B (en) * | 1984-10-12 | 1986-05-28 | Akzo Nv | Release system for two or more active substances |
US4596576A (en) * | 1984-10-12 | 1986-06-24 | Akzo N.V. | Release system for two or more active substances |
US4645502A (en) | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
SE8602666D0 (en) | 1986-06-16 | 1986-06-16 | Leo Ab | INTRAVAGINAL DEVICES |
US4938759A (en) | 1986-09-02 | 1990-07-03 | Alza Corporation | Transdermal delivery device having a rate controlling adhesive |
CA1331563C (en) | 1987-08-03 | 1994-08-23 | Gaylen M. Zentner | Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins |
DE3879031T2 (en) | 1987-08-08 | 1993-06-24 | Akzo Nv | CONCEPTUAL IMPLANT. |
US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
NO179479C (en) | 1988-03-11 | 1996-10-16 | Teikoku Seiyaku Kk | Process for the preparation of an intravaginal pharmaceutical preparation |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US5002540A (en) | 1989-05-22 | 1991-03-26 | Warren Kirschbaum | Intravaginal device and method for delivering a medicament |
US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
HU208495B (en) | 1990-06-27 | 1993-11-29 | Alkaloida Vegyeszeti Gyar | Process for producing retarde pharmaceutical compositions |
IE67345B1 (en) | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US5302397A (en) * | 1991-11-19 | 1994-04-12 | Amsden Brian G | Polymer-based drug delivery system |
US6013853A (en) | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
EP0566135A1 (en) | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Transmucosal composition comprising a peptide and a cytidine derivative |
CA2098889A1 (en) | 1992-07-06 | 1994-01-07 | Takashi Chinuki | Slow-releasing medicated resin moldings and process for producing the same |
US5482702A (en) * | 1993-04-27 | 1996-01-09 | Church & Dwight Co., Inc. | Hydrophilic polymer-coated microcrystallites of bicarbonate salt |
JPH08512054A (en) | 1993-06-25 | 1996-12-17 | アルザ・コーポレーション | Inclusion of poly-N-vinylamide in transdermal system |
GB2282384B8 (en) | 1993-08-18 | 1997-09-04 | Europ Economic Community | Drug delivery agents incorporating mitomycin |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
CA2176824A1 (en) | 1993-12-27 | 1995-07-06 | Hiroshi Kuroda | Percutaneously absorbable preparation |
FR2717688B1 (en) | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Transdermal matrix system for administration of an estrogen and / or an EVA-based progestin. |
FI97944C (en) | 1994-07-05 | 1997-03-25 | Leiras Oy | Active substance delivery device |
US5681568A (en) | 1994-08-19 | 1997-10-28 | Cambridge Neuroscience, Inc. | Device for delivery of substances and methods of use thereof |
US5593965A (en) | 1994-10-20 | 1997-01-14 | Creighton University | Anti-tumor effects of GnRH-III |
IL116433A (en) | 1994-12-19 | 2002-02-10 | Galen Chemicals Ltd | INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS |
WO1996031197A1 (en) | 1995-04-03 | 1996-10-10 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
US5601839A (en) | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
ATE207736T1 (en) * | 1995-07-04 | 2001-11-15 | Akzo Nobel Nv | ANNUAL DEVICE |
FR2739032B1 (en) | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | TRANSDERMAL MATRIX SYSTEM FOR ADMINISTRATION OF AN ESTROGEN AND / OR AN EVA-BASED PROGESTIVE, PROCESS FOR PREPARATION AND THERAPEUTIC USE |
US5780435A (en) | 1995-12-15 | 1998-07-14 | Praecis Pharmaceuticals Incorporated | Methods for treating prostate cancer with LHRH-R antagonists |
US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US5869081A (en) | 1996-06-28 | 1999-02-09 | The Population Council | Progesterone vaginal ring for treatment of infertility |
US6139873A (en) | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
US5972372A (en) | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
US5945128A (en) | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
PT839525E (en) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | PROLONGED LIBERATION PREPARATION |
US5985861A (en) | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
JPH10138432A (en) | 1996-11-14 | 1998-05-26 | Teijin Ltd | Biaxially oriented laminate polyester film for magnetic tape |
US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
JPH10279499A (en) | 1997-04-04 | 1998-10-20 | Takeda Chem Ind Ltd | Preparation applicable to uterine mucosa |
TW358031B (en) | 1997-04-11 | 1999-05-11 | Akze Nobel N V | Drug delivery system for 2 or more active substances |
AR012448A1 (en) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | COMPOSITION IN THE FORM OF MICROCAPSULES OR IMPLANTS COMPRISING A BIODEGRADABLE CONTAINER, POLYMER OR CO-POLYMER, OR A MIXTURE OF SUCH EXCIPIENTS, AND AN ACTIVE SUBSTANCE OR MIXTURE OF ACTIVE SUBSTANCES, PROCEDURE FOR THE PREPARATION OF A SUBSTANCE IN A SUBSTANCE |
US6572874B1 (en) | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
US6905701B2 (en) | 1997-06-11 | 2005-06-14 | Umd, Inc. | Formulations for transmucosal vaginal delivery of bisphosphonates |
US6197327B1 (en) | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6416779B1 (en) | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
US6039968A (en) * | 1997-06-24 | 2000-03-21 | Hoechst Marion Roussel | Intravaginal drug delivery device |
US5941844A (en) | 1997-11-17 | 1999-08-24 | Alza Corporation | Method and device for controlling mammalian reproductive cycle |
ES2378675T3 (en) | 1997-12-30 | 2012-04-16 | Intarcia Therapeutics, Inc | Delivery system of a beneficial agent with a sealing membrane |
USD442688S1 (en) | 1998-01-28 | 2001-05-22 | N.V. Organon | Vaginal ring applicator |
EP0940678A1 (en) | 1998-03-02 | 1999-09-08 | Akzo Nobel N.V. | Analytical test device |
US5945123A (en) | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
ATE313422T1 (en) | 1998-05-01 | 2006-01-15 | Duramed Pharmaceuticals Inc | METHOD FOR INJECTION MOLDING DEVICES WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND DEVICE PRODUCED THEREFROM |
US6218367B1 (en) | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6159491A (en) | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
WO2001014478A1 (en) | 1999-08-25 | 2001-03-01 | Dai-Ichi Kogyo Seiyaku Co., Ltd | Gel-form molded resin composition, packaged volatile gel-form chemical, and process for producing the same |
US6264973B1 (en) | 1999-08-26 | 2001-07-24 | Fei Enterprises, Ltd. | Apparatus and method for anesthetizing the cervical region of a female |
WO2001026648A1 (en) | 1999-10-13 | 2001-04-19 | Senju Pharmaceutical Co., Ltd. | Ophthalmic adhesive preparations for percutaneous absorption |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
US6687178B1 (en) * | 2001-02-23 | 2004-02-03 | Western Digital (Fremont), Inc. | Temperature dependent write current source for magnetic tunnel junction MRAM |
-
2004
- 2004-04-29 CA CA2523859A patent/CA2523859C/en not_active Expired - Lifetime
- 2004-04-29 WO PCT/US2004/013172 patent/WO2004096151A2/en active Application Filing
- 2004-04-29 AT AT04760436T patent/ATE461681T1/en not_active IP Right Cessation
- 2004-04-29 EP EP04760436A patent/EP1620060B1/en not_active Expired - Lifetime
- 2004-04-29 JP JP2006513416A patent/JP4898431B2/en not_active Expired - Lifetime
- 2004-04-29 AU AU2004233997A patent/AU2004233997C1/en active Active
- 2004-04-29 DE DE602004026173T patent/DE602004026173D1/en not_active Expired - Lifetime
- 2004-04-29 US US10/835,414 patent/US7833545B2/en active Active
-
2008
- 2008-05-22 US US12/125,629 patent/US20090060982A1/en not_active Abandoned
- 2008-05-22 US US12/125,571 patent/US7838024B2/en not_active Expired - Lifetime
- 2008-05-22 US US12/125,593 patent/US7829112B2/en active Active
- 2008-05-22 US US12/125,606 patent/US20080286339A1/en not_active Abandoned
- 2008-05-22 US US12/125,581 patent/US7883718B2/en active Active
-
2011
- 2011-01-14 US US13/007,222 patent/US20120202742A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7838024B2 (en) | 2010-11-23 |
US7883718B2 (en) | 2011-02-08 |
EP1620060A2 (en) | 2006-02-01 |
EP1620060A4 (en) | 2007-11-28 |
AU2004233997B2 (en) | 2009-12-17 |
WO2004096151A3 (en) | 2006-05-11 |
US20070196433A1 (en) | 2007-08-23 |
US20080248017A1 (en) | 2008-10-09 |
US20120202742A1 (en) | 2012-08-09 |
US7833545B2 (en) | 2010-11-16 |
WO2004096151A2 (en) | 2004-11-11 |
ATE461681T1 (en) | 2010-04-15 |
US20090274654A1 (en) | 2009-11-05 |
US20080286339A1 (en) | 2008-11-20 |
AU2004233997B8 (en) | 2010-01-14 |
US20090060982A1 (en) | 2009-03-05 |
DE602004026173D1 (en) | 2010-05-06 |
EP1620060B1 (en) | 2010-03-24 |
AU2004233997B9 (en) | 2013-01-10 |
JP2007525461A (en) | 2007-09-06 |
AU2004233997A1 (en) | 2004-11-11 |
AU2004233997C1 (en) | 2014-01-30 |
US20080286322A1 (en) | 2008-11-20 |
JP4898431B2 (en) | 2012-03-14 |
CA2523859C (en) | 2011-08-02 |
US7829112B2 (en) | 2010-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2523859A1 (en) | Methods and devices for the sustained release of multiple drugs | |
US4629449A (en) | Vaginal dispenser for dispensing beneficial hormone | |
Sitruk-Ware et al. | Contraception technology: past, present and future | |
US4961931A (en) | Method for the management of hyperplasia | |
US4250611A (en) | Process for making drug delivery device with reservoir | |
US4578076A (en) | Medicated intracervical and intrauterine devices | |
JP2007525461A5 (en) | ||
EP2359807B1 (en) | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | |
CN102088954A (en) | An intrauterine delivery system for contraception | |
Sitruk-Ware | Contraception: an international perspective | |
US8980304B2 (en) | Barrel-shaped vaginal ring | |
TWI669134B (en) | Copper intrauterine system | |
JP6796693B2 (en) | Formulations and methods for vaginal delivery of antiprogestin | |
Sitruk-Ware | Delivery options for contraceptives | |
US20200383906A1 (en) | Hormonal contraception using a vaginal ring which releases estriol and trimegestone | |
Economidis et al. | Pharmacological female contraception: an overview of past and future use | |
Shearman | Recent advances in contraceptive technology | |
Kuttenn | Progestogen-only methods of contraception |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |